LIBTAYO (cemiplimab-rwlc) is a prescription medicine used to treat adults with NSCLC. LIBTAYO may be used alone as a first treatment option when your lung cancer has not spread outside your chest ...

Currently, the flagship of Regeneron's oncology franchise is Libtayo (cemiplimab-rwlc), which is an anti-PD-1 monoclonal antibody that is approved for the treatment of several types of cancer.

Regeneron Pharmaceuticals Stock Price, Consensus and EPS Surprise REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in ...

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

regarding the combination of cemiplimab-rwlc (Libtayo) and chemotherapy in treating locally advanced or metastatic penile carcinoma, and how might this impact future treatment options for this rare ...

Phase 2 EPIC trial data (ISRCTN95561634), presented at the 2025 ASCO Genitourinary Cancer Symposium, showed that cemiplimab-rwlc (Libtayo) combined with standard platinum-based chemotherapy ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...